Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

Launched by FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how to better diagnose and treat patients with autoimmune cytopenias, which are conditions where the immune system mistakenly attacks blood cells. Specifically, the study focuses on autoimmune hemolytic anemia (where red blood cells are destroyed), immune thrombocytopenia (where the blood has too few platelets), and chronic neutropenia (where there aren’t enough white blood cells). Researchers want to understand which tests work best for diagnosing these conditions, how different treatments affect patients, and how these conditions might change over time.

To participate in the study, individuals must be at least 18 years old and have a confirmed diagnosis of one of the targeted autoimmune cytopenias. They should be available for follow-up over three years and able to give their consent to join the study. During the trial, participants will undergo standard tests to assess their condition and provide samples of blood and stool. This information will help doctors learn more about the diseases and improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of autoimmune cytopenias (AIHA/ITP/CIN/AIN)
• • age \>/= 18 years
• • ability to sign informed consent
• • availability to undergo 3 year follow up
• • for the subgroup of patients with myelodysplastic syndrome: bone marrow evaluation showing \>/= 10% dysplastic features of at least one lineage along with MDS defining cytopenia and/or MDS defining cytogenetics.
• Exclusion Criteria:
• • any condition impeding the acquisition of the informed consent
• • immune cytopenia diagnosis preceding \>/= 6 months the enrolment